DNLI
$20.71
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Recent News
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build
Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a broadening pipeline during a discussion hosted by Leerink Partners analyst Marc Goodman. Chief Executive Officer Ryan Watts and Chief Commercial Officer Katie Peng focused on
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed?
Earlier in March 2026, Denali Therapeutics Inc. presented at the UBS Biotech Summit and Jefferies Biotech on the Beach Summit in Miami, highlighting its rare disease programs and blood–brain barrier platform. Investor attention is increasingly centered on tividenofusp alfa for Hunter syndrome, with an upcoming FDA action date viewed as a key test of Denali’s therapeutic approach. We’ll now examine how anticipation around the FDA decision on tividenofusp alfa could influence Denali’s...
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains
Denali Therapeutics (DNLI) has been drawing attention after recent share price moves, with the stock up 27.2% year to date and delivering a 39% total return over the past year. This performance has prompted fresh investor scrutiny. See our latest analysis for Denali Therapeutics. The recent 7 day share price return of 5.1% and 90 day share price return of 15.1%, against a 1 year total shareholder return of 39%, point to momentum that has picked up in the short term after a weaker multi year...
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop
Denali Therapeutics (NASDAQ:DNLI) used an analyst call from the 2026 WORLD Symposium in San Diego to highlight new and updated data from its enzyme transport vehicle (ETV) franchise, including clinical follow-up for tividenofusp alfa (TIVI) in Hunter syndrome (MPS II), preliminary Phase 1/2 biomarke